Aberdeen Group
IMRX icon

Aberdeen Group’s Immuneering IMRX Stock Holding History

Aberdeen Group’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.21M Buy
+784,951
New +$3.71M ﹤0.01% 803

Other funds holding IMRX

Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $444M AUM 151.5% 1-Year Est. Return
Levin Capital Strategies
Levin Capital Strategies New York $1.42B AUM 19.05% 1-Year Est. Return
PVG Asset Management
PVG Asset Management Golden, Colorado $147M AUM 52.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Wealth Effects
Wealth Effects Boston, Massachusetts $370M AUM 63.53% 1-Year Est. Return
Clearstead Advisors
Clearstead Advisors Cleveland, Ohio $10.8B AUM 17.88% 1-Year Est. Return

Aberdeen Group's IMRX Position: Q3 2026 in Review

Aberdeen Group opened a new position in Immuneering (IMRX) in Q3 2026: 784,951 shares worth $3.21M. The stake represents ﹤0.01% of the portfolio and ranks #803 among its holdings.

46 funds tracked by Wall St. Rank hold IMRX as of Q3 2026.

  • Aberdeen Group held 784,951 shares of Immuneering worth $3.21M as of Q3 2026.
  • Immuneering was a new Aberdeen Group position in Q3 2026.
  • Immuneering made up ﹤0.01% of Aberdeen Group's portfolio in Q3 2026, its #803 holding.
  • 46 funds tracked by Wall St. Rank held Immuneering as of Q3 2026.

Based on Aberdeen Group's 13F filing for Q3 2026, filed 6 Nov 2026.